← All trials
NCT06273943
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Oct 30, 2025
- Completion date
- Oct 30, 2026
- First posted
- Feb 23, 2024
- Last posted
- Feb 23, 2024
- Enrollment
- 322
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of FranceLead sponsor
- University of ParisOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.